Reportedly, the global sleep apnea device market is growing at a considerable CAGR of 7.8% from 2022 to 2028. However, the rising availability of alternative methods along with high-cost involvement in major medical devices is some factors that are hindering the growth of the global sleep apnoea device market across the globe.
This is where a London-based startup Acurable, an award-winning wearable medical devices company, comes into the picture with its offering that simplifies sleep apnoea detection. The company has secured €11 million in Series A funding. The investment was led by Kibo Ventures (which invested in HRtech startup Circulor), along with Mundi Ventures, Kindred Capital (which backed Lottie), and Comprador Holdings among others.
Expand its sleep testing kit
The funds will be used to accelerate the international expansion of its first product AcuPebble SA100 and drive the company towards its ambition to become the preferred solution for home sleep testing worldwide. Acurable’s international expansion (focused on North America and Europe) brings it one step closer to solving the current unmet needs in diagnosis and monitoring of OSA, a significant issue affecting nearly one billion people worldwide. Also, the company will continue investing in new products for chronic respiratory and cardiovascular conditions.
This funding follows the recent announcement of a strategic distribution agreement with Nyxoah to provide the AcuPebble SA100 home sleep test to the German market.
Professor Esther Rodriguez-Villegas, commented: “The response to AcuPebble SA100 since its launch has been incredible, and we are thrilled to see the product being used to help patients and clinicians in the real world. This funding will help us reach our initial goal of diagnosing one million patients and gives us the opportunity to continue working on new products that will fundamentally improve the lives of millions of people living with severe chronic conditions.”
Sonia Fernández, Partner at Kibo Ventures, said: “We are delighted to be joining Acurable’s exciting journey. AcuPebble has the potential to transform the way sleep apnoea and other chronic conditions are diagnosed and monitored. It’s much more accurate and easier to use than other devices, and we believe it’s a huge step forward for global healthcare. This is still just the beginning for Acurable, and I cannot wait for what comes next.”
Idea behind Acurable
The foundational research behind Acurable began in 2004 at Imperial College London, when Prof. Esther Rodriguez-Villegas and her team decided to investigate the challenges associated with accurate respiratory monitoring. After ten years, they gained vast and unique knowledge about novel wearable devices that could be created to solve a wider range of healthcare problems, thereby creating Acurable.
Professor Esther Rodriguez-Villegas, the inventor of the AcuPebble technology, and co-CEO and founder of Acurable, is a renowned scientist in the world and has been awarded some of the highest recognitions in her field.
Addresses obstructive sleep apnoea
Acurable’s first product AcuPebble SA100 simplifies obstructive sleep apnoea (OSA) detection and monitoring by enabling fully automated testing of patients at home for the first time. After successfully launching AcuPebble SA100 in the UK and Spain in 2021, Acurable is now looking to scale up in these two countries and expand into further European markets and North America.
It is the first wearable medical device to obtain a CE mark in Europe for the automated diagnosis of obstructive sleep apnoea at home. AcuPebble provides an instant diagnostic sleep test result that is equivalent in accuracy to the ambulatory gold standard – cardiorespiratory polygraphy, which requires time-consuming clinical interpretation. The AcuPebble sensor is very small and non-invasive.
The post Medical wearable startup Acurable picks €11M for its home sleep testing device appeared first on Tech Funding News.